Get started
Author

M Maccari

Observed name: M. Maccari
ORCID: 0009-0002-2593-4267
Observed ORCID: 0009-0002-2593-4267
OpenAlex ID: A5089379642
297P The genetic profile of primary and recurrent gliomas: A mono-institutional experience using next-generation sequencing
2022 · M. Padovan, M. Maccari, et al. · Annals of Oncology · 2
502MO Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy)
2023 · G. Cerretti, M. Padovan, et al. · Annals of Oncology · 1
PDF
Os09.2.a Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed Mgmt-methylated, Idh Wildtype Glioblastoma: a Phase I Dose-finding Study (regoma-2, Eudra Ct N° 2021-001604-15)
2023 · M Padovan, G De Salvo, et al. · Neuro-Oncology · 1
PDF
P18.05.A Bevacizumab in atypical and anaplastic meningiomas: the BEMEN study
2022 · G Cerretti, A Bosio, et al. · Neuro-Oncology · 1
PDF
P13.14.a Regorafenib Versus Local Standard of Care in Patients With Grade 2-3 Meningioma No Longer Eligible for Loco-regional Treatments: the Mirage Trial
2025 · A Bosio, G Cerretti, et al. · Neuro-Oncology
PDF
P17.39.a Impact of Frailty on Surgical Outcomes in Patients Affected by Glioblastoma: a Multicenter Analysis With Multivariate and Machine Learning Approaches.
2025 · M Caffo, L Conte, et al. · Neuro-Oncology
PDF
P12.32.a Molecular Stratification by Pten Status Reveals Differential Second-line Therapy Responses in Recurrent Idh-wildtype Glioblastoma
2025 · E Cella, M Padovan, et al. · Neuro-Oncology
PDF
P12.21.b a Phase 1, First-in-human Study of Regorafenib Plus Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed Mgmt Methylated, Idh Wildtype Glioblastoma: Regoma-2 Trial
2025 · M Padovan, M Simonelli, et al. · Neuro-Oncology
PDF
P14.27.b Long-term Outcomes and Molecularly-guided Management of Adult Medulloblastoma: Data From a Single-institution Experience
2025 · A Bosio, M Maccari, et al. · Neuro-Oncology
PDF
P17.40.b Effectiveness of Target Therapy in Adult and Pediatric Recurrent High Grade Glioma Patients With Brafv600e Mutation or Ntrk Fusion: a Real-life Multicentric Italian Analysis.
2025 · E Cella, M Padovan, et al. · Neuro-Oncology
PDF
WITHDRAWN: 675P Molecular stratification by PTEN status reveals differential second-line therapy responses in recurrent IDH-wildtype glioblastoma
2025 · M. Polano, E. Cella, et al. · Annals of Oncology
700P Long-term outcomes and molecularly-guided management of adult medulloblastoma: Data from a single-institution experience
2025 · A. Bosio, M. Maccari, et al. · Annals of Oncology
P20.15.b Molecular Characterization of Adult Non-glioblastoma Central Nervous System (cns) Tumors to Identify Potential Targettable Alterations
2024 · M Padovan, A Bosio, et al. · Neuro-Oncology
PDF
P18.17.b Effectiveness of Dabrafenib-trametinib and Larotrectinib in Adult Recurrent Glioblastoma Patients: a Real-life Cohort Analysis From 3 Italian Centers
2024 · M Padovan, E Cella, et al. · Neuro-Oncology
PDF
Js03.5.a Do Patients With Molecularly-defined Glioblastoma Share the Same Clinical Characteristics and Outcome of Histologically-defined Glioblastoma? a Multicentric Study From the Italian Association of Neuro-oncology (aino)
2024 · F Bruno, A Pellerino, et al. · Neuro-Oncology
PDF
461P Effectiveness of dabrafenib-trametinib and larotrectinib in adult recurrent glioblastoma patients: A real-life cohort analysis from 3 Italian centers
2024 · M. Padovan, E. Cella, et al. · Annals of Oncology
PDF
P20.14.b Systemic Therapy for Recurrent Adult Intracranial and Spinal Ependymomas: a Mono-institutional Experience
2023 · M Maccari, M Padovan, et al. · Neuro-Oncology
PDF
P17.06.b Targeted Therapy Matched to Genomic Alterations (brafv600e, Ntrk, Fgfr, Ros1, Pik3ca, Pten) in Patients With Recurrent Idh Wildtype Glioblastoma: a Real-life Cohort Analysis From Veneto Institute of Oncology, Padua (italy)
2023 · M Padovan, C De Toni, et al. · Neuro-Oncology
PDF
P02.02.A Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience
2022 · M Padovan, M Maccari, et al. · Neuro-Oncology
PDF
Works count: 19
Citation count: 5
H-index: 1
I10-index:
Year
Topic
Type